Search research articles
Contact Us
Filters
Showing results (41-50 of 85) with videos related to
Page
of 9
Sort By:
Science (New York, N.Y.)
|
January 7, 2017
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer
Ping Mu, Zeda Zhang, Matteo Benelli, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Hanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
JCO Precision Oncology
|
February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Maria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Jonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Cancer Discovery
|
May 8, 2020
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis
Josef Leibold, Marcus Ruscetti, Zhen Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2022
The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer
Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration
Wassim Abida, Akash Patnaik, David Campbell, et al.
Nature Cancer
|
July 14, 2021
Accelerating precision medicine in metastatic prostate cancer
Joaquin Mateo, Rana McKay, Wassim Abida, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 85) with videos related to
Sort By:
Page
of 9
Science (New York, N.Y.)
|
January 7, 2017
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer
Ping Mu, Zeda Zhang, Matteo Benelli, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2021
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Hanna Tukachinsky, Russell W Madison, Jon H Chung, et al.
JCO Precision Oncology
|
February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium
Maria I Carlo, Veda N Giri, Channing J Paller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2024
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Jonathan Chou, Troy M Robinson, Emily A Egusa, et al.
Cancer Discovery
|
May 8, 2020
Somatic Tissue Engineering in Mouse Models Reveals an Actionable Role for WNT Pathway Alterations in Prostate Cancer Metastasis
Josef Leibold, Marcus Ruscetti, Zhen Cao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 7, 2022
The Impact of PIK3R1 Mutations and Insulin-PI3K-Glycolytic Pathway Regulation in Prostate Cancer
Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration
Wassim Abida, Akash Patnaik, David Campbell, et al.
Nature Cancer
|
July 14, 2021
Accelerating precision medicine in metastatic prostate cancer
Joaquin Mateo, Rana McKay, Wassim Abida, et al.
Page
of 9